XXII

#5054
22nd Century Group, Inc - Common Stock
2.3 2 USD
-0.01%
Market Price
Settore: Beni di Consumo Difensivi
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.32
2.33
Intervallo Annuale
0.27
7.32
Variazione giornaliera
-0.85%
Variazione Mensile
-45.67%
Variazione di 6 mesi
-41.12%
Variazione Annuale
-59.30%
Chiusura Precedente
2.3 4
Open
2.3 3
Minimo
2.3 2
Massimo
2.3 3
Volume
4
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 01 Sep 2026
22Nd Century Group, Inc. current report, 01 September 2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
22Nd Century Group, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
22Nd Century Group, Inc. quarterly report, Q1 FY2026
10-Q

22Nd Century Group, Inc. current report, 31 October 2017

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by 22nd Century Group, Inc. on October 31, 2017. The filing primarily addresses the appointment of a new senior executive and the associated compensatory arrangements.

Key Financial Metrics

The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details:

  • Base Salary: $250,000 annually for the new Senior Vice President.
  • Severance: Six months of base salary upon termination without Cause or for Good Reason.
  • Equity Grants:
    • 900,000 Time Vesting Options at an exercise price of $2.12 per share.
    • 300,000 Performance Vesting Options at an exercise price of $2.12 per share.

Material Changes

The material change reported is the appointment of James E. Swauger, Ph.D., as Senior Vice President of Science and Regulatory Affairs. Dr. Swauger brings 23 years of experience from Reynolds American Inc., where he served as Vice President of Regulatory Oversight from 2008 to 2016.

Outlook, Risks, and Management Commentary

Performance Milestones: The Performance Vesting Options are tied to specific regulatory milestones regarding the Company's "Very Low Nicotine MRTP candidate known as 'BRAND A'":

  • 100,000 options vest upon submission of a complete MRTP application to the FDA by March 31, 2019.
  • 100,000 options vest upon submission of the application to the FDA's Tobacco Products Scientific Advisory Committee (TPSAC).
  • 100,000 options vest upon securing FDA MRTP authorization by December 31, 2020.

Change in Control: In the event of a Change in Control, Time Vesting Options accelerate, but unvested Performance Vesting Options are forfeited.

Investor Verification Checklist

  • Verify the vesting schedule and performance criteria for the 1.2 million total stock options granted to Dr. Swauger.
  • Confirm the status of the "BRAND A" MRTP application and its timeline relative to the March 31, 2019 deadline.
  • Review the full Employment Agreement (Exhibit 10.1) for definitions of "Cause" and "Good Reason."
  • Check subsequent filings for updates on the FDA regulatory process for the Very Low Nicotine product.

Notizie